Introduction
============

The Prove-it™ Sepsis assay is a rapid, broad-range PCR and microarray-based assay designed to identify the majority of sepsis-causing bacteria from positive blood cultures. The pathogen panel covers 50 Gram-negative and Gram-positive bacterial species (Table [1](#T1){ref-type="table"}). It also reports methicillin resistance by detecting the mecA gene. The assay time is 3 hours. Our objective was to conduct a performance evaluation study for Prove-it™ Sepsis according to the EN 13612-standard (Performance evaluation of *in vitro*diagnostic medical devices) and to compare obtained results with those of current culture-based diagnostics. We evaluated the sensitivity, specificity and time to result of Prove-it™ Sepsis in two major teaching hospitals in Helsinki and London.

###### 

Bacteria and an antibacterial resistance marker identified by the Prove-it™ Sepsis assay

  **Gram-negative**                           **Gram-positive**                                   **Antibacterial resistance**
  ------------------------------------------- --------------------------------------------------- ------------------------------------
  *Neisseria meningitidis*                    *Staphylococcus aureus*                             Methicillin resistance marker mecA
  *Enterobacter aerogenes*                    *Staphylococcus epidermidis*                        
  *Enterobacter cloacae*                      *Coagulase-negative Staphylococcus*^d^              
  *Escherichia coli*                          *Streptococcus pyogenes*                            
  *Klebsiella oxytoca*                        *Streptococcus agalactiae*                          
  *Klebsiella pneumoniae*                     *Streptococcus dysgalactiae* subsp. *equisimilis*   
  *Proteus mirabilis*                         *Streptococcus pneumoniae*                          
  *Proteus vulgaris*                          *Enterococcus faecalis*                             
  *Salmonella enterica*subsp. *enterica*^a^   *Enterococcus faecium*                              
  *Serratia marcescens*                       *Listeria monocytogenes*                            
  *Enterobacteriaceae family*^b^              *Clostridium perfringens*                           
  *Acinetobacter baumannii*                                                                       
  *Pseudomonas aeruginosa*                                                                        
  *Stenotrophomonas maltophilia*                                                                  
  *Haemophilus influenzae*                                                                        
  *Campylobacter jejuni/coli*                                                                     
  *Bacteroides fragilis*group^c^                                                                  

^a^*Salmonella enterica*subsp. *enterica*covers at least the following serovars: *Enteritidis*, *Oranienburg*, *Othmarschen*, *Paratyphi*, *Stanley*, *Typhi*, *Typhimurium*, Virchow, Group A, B, C, D. ^b^Enterobacteriaceae covers at least the following species: *Citrobacter amalonaticus*, *Citrobacter freundii*, *Citrobacter koseri*, *Citrobacter braakii*, *Enterobacter hormaechei*, *Enterobacter sakazakii*, *Kluyvera intermedia*, *Morganella morganii*, *Pantoea agglomerans*, *Providencia rettgeri*, *Providencia stuartii*, *Yersinia enterocolitica*, *Yersinia pseudotuberculosis*. ^c^*Bacteroides fragilis*covers at least the following species: *B. fragilis*, *B. vulgatus*, *B. thetaiotaomicron*. ^d^Coagulase-negative *Staphylococcus*covers at least the following species: *S. capitis*, *S. lugdunensis*, *S. haemolyticus*, *S. hominis*, *S. saprophyticus*, *S. warneri*, *S. xylosus.*

Materials
=========

A total of 3,318 blood samples from patients with suspected sepsis were collected. Blood culture bottles of BacT/ALERT 3D (bioMérieux) and BACTEC 924 (Becton Dickinson) were incubated for a total of 6 days or until flagged as positive.

Methods
=======

DNA was extracted from blood cultures using the automated DNA extraction instrument easyMAG (bioMérieux) prior to the Prove-it™ Sepsis assay. Conventional blood culture was conducted in parallel and results were only revealed for comparison at the statistical analysis stage. Discordant results were studied by DNA sequencing and case-by-case review of original microbiology laboratory data.

Results
=======

Of the analyzed 3,318 blood cultures, 2,107 yielded a pathogen by conventional techniques. Of these, 302 samples contained microbes not covered by Prove-it™ Sepsis, and an additional 137 cultures contained more than one organism. Sensitivity and specificity for Prove-it™ Sepsis were 94.7% and 98.7%, respectively. Of particular significance was the assay\'s faultless ability to differentiate MRSA from MSSA and from CNS. Furthermore, it provided results on average 1 day earlier than reference methods.

Conclusion
==========

Prove-it™ Sepsis was considered to be a fast, robust, and high-performance diagnostic platform, which is easily implemented into everyday laboratory workflow. Both study sites identified cases where timely information provided by Prove-it™ Sepsis would have significantly improved patient management. Examples include more rational management and antibiotic choice subsequent to earlier differentiation of Gram-positive cocci in clumps into MRSA, MSSA, or CNS, and earlier speciation of Gram-negative organisms. Prove-it™ Sepsis is further configured for detection of *Candida*spp. and new bacterial targets. The assay now identifies 60 out of the 302 samples not covered during the evaluation, increasing the pathogen coverage from 86% to 89%. The earlier speciation provided by Prove-it™ Sepsis could contribute to faster, more evidence-based patient management and, thus, positive outcomes.
